Status:
COMPLETED
Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis
Lead Sponsor:
Pfizer
Conditions:
Juvenile Idiopathic Arthritis
Eligibility:
All Genders
2-18 years
Phase:
PHASE2
PHASE3
Brief Summary
Evaluate long-term safety and tolerability of tofacitinib in patients with JIA, who have previously participated in tofacitinib JIA studies.
Detailed Description
This is a Phase 2/3, long term, open-label, follow-up study. Subjects will have previously participated in qualifying/index JIA studies of tofacitinib. Those who have already completed such participat...
Eligibility Criteria
Inclusion
- Pediatric subjects with JIA aged from 2 to less than 18 years who met entry criteria for the qualifying/index study and in the opinion of the investigator have sufficient evidence of JIA disease activity to warrant use of tofacitinib as a DMARD. Subjects turning 18 years of age during participation in the qualifying/index study or subsequently will be eligible for participation in this study.
- The subject has discontinued disallowed concomitant medications for the required time prior to the first dose of study drug, as defined in Appendix 1, and is taking only those concomitant medications in doses and frequency allowed by the protocol.
- Fertile male subjects and female subjects of childbearing potential who are, in the opinion of the investigator, sexually active and at risk for pregnancy with their partner(s) must be using a highly effective method of contraception as outlined in this protocol throughout the study and for at least 28 days after the last dose of study medication.
- Subjects must have previously completed participation in a qualifying study of tofacitinib for the treatment of JIA. Subjects who have required earlier discontinuation of treatment in a qualifying study for reasons other than tofacitinib related serious adverse events may be eligible.
Exclusion
- persistent oligoarthritis, and undifferentiated JIA.
- Infections:
- Chronic infections.
- Any infection requiring hospitalization, parenteral antimicrobial therapy or judged to be opportunistic by the investigator within the 3 months prior to the first dose of study drug.
- Any treated infections within 2 weeks of baseline visit.
- A subject known to be infected with human immunodeficiency virus (HIV), hepatitis B or hepatitis C virus.
- History of infected joint prosthesis with prosthesis still in situ.
- History of recurrent (more than one episode) herpes zoster or disseminated (a single episode) herpes zoster or disseminated (a single episode) herpes simplex.
Key Trial Info
Start Date :
March 18 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 12 2025
Estimated Enrollment :
302 Patients enrolled
Trial Details
Trial ID
NCT01500551
Start Date
March 18 2013
End Date
February 12 2025
Last Update
August 5 2025
Active Locations (104)
Enter a location and click search to find clinical trials sorted by distance.
1
Arkansas Children's Hospital
Little Rock, Arkansas, United States, 72202
2
Loma Linda University Children'S Hospital
Loma Linda, California, United States, 92354
3
Loma Linda University Clinical Trials Center
Loma Linda, California, United States, 92354
4
Loma Linda University Eye Institute
Loma Linda, California, United States, 92354